Navigation Links
BioMedix™ Receives Patent for Its Innovative Collaborative Care Business Method
Date:7/21/2011

ST. PAUL, Minn., July 21, 2011 /PRNewswire/ -- BioMedix™, a leader in providing integrated Health Information Technology (HIT) products and services, has been awarded a U.S. Patent recognizing its innovative solutions and methods for detecting and managing cardiovascular disease.

On July 19, 2011, the United States Patent & Trademark Office issued U.S. Patent Number 7,983,930, entitled "System and Method for Testing for Cardiovascular Disease," crediting BioMedix™ President & CEO John Romans as inventor. The patent is now part of the growing portfolio of BioMedix™ intellectual property on innovative medical technologies, addressing testing, diagnosis and administrative processing across remote locations. The underlying concept, comprised of a collaborative care model utilizing the integrated suite of BioMedix™ solutions, facilitates partnership between primary care facilities and specialists, taking advantage of the specialists' expertise while still allowing testing to be easily performed at a variety of accessible test locations.

"This development allows specialists to have a virtual presence in every primary care setting, enabling improved care through cost-effective coordination and collaboration of physicians in different physical locations," stated John Romans.

The initial application of this invention has supported the improved detection, treatment and management of an under-diagnosed and costly vascular condition called Peripheral Artery Disease (P.A.D.). The BioMedix™ collaborative care network reduces time and travel for patient treatment while supporting improved patient outcomes. As part of this advanced web-based platform, BioMedix™ PADnet™ Disease Management System 2.0 provides a turnkey collaborative care solution for finding and managing patients with vascular disease utilizing the BioMedix™ PADnet™+, a non-invasive device for in-office testing. With a disease detection network made up of local hub-and-spoke networks across the country, BioMedix™ products and initiatives aim to address gaps in healthcare and disease detection.

Austen Zuege, shareholder at the intellectual property law firm Kinney & Lange, P.A. in Minneapolis said, "I am pleased to see the issuance of this patent, which demonstrates the high level of innovation at BioMedix™."

About BioMedix™

BioMedix™ is a leader in Health Information Technology (HIT) software, products and services that connect Podiatric Physicians, Primary Care Physicians, vascular labs, vascular specialists and healthcare systems in a continuum of collaborative care. We provide the only integrated suite of hardware, software and online services designed to cost-effectively detect vascular disease. Our award-winning suite of medical devices, advanced practice management and Electronic Health Record (EHR) software and web-based solutions give providers a more complete view of patient care. For more information about BioMedix™ products, call 877-854-0014 or log on to www.BioMedix.com.


'/>"/>
SOURCE BioMedix
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMedix™ Announces John Martin, MD, FACS, as Medical Director
2. BioMedix™ Now Exclusive Industry Distributor of the APMA Coding Resource Center
3. Agendia Receives €1.27 Million in Funding from the EUs Seventh Framework Programme
4. Cephalon Receives FDA Approval for Risk Evaluation and Mitigation Strategy for FENTORA and ACTIQ
5. Perrigo Receives FDA Approval to Market Coated Cinnamon Nicotine Gum
6. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
7. UCLA Receives Six UC Health Quality Grants to Improve Hospital Care
8. Sequana Medical Receives CE Mark Approval for the ALFApump™ System and Adds Key Executive to Team
9. Chartwell Pharmaceuticals Receives Official FDA Registration
10. GlaxoSmithKline Receives FDA Approval for BOOSTRIX® to Help Prevent Whooping Cough in Adults 65 Years and Older
11. Sonitus Medical Receives Second FDA Clearance for SoundBite™ Hearing System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
(Date:3/29/2017)...  Maxor National Pharmacy Services, LLC ("Maxor"), a leading ... Leah Bailey as General Counsel.  Bailey will serve ... With more than 13 years of experience ... on health care, Bailey joins the Maxor team coming ... advised the PBM, Specialty, and Mail Order business areas ...
(Date:3/29/2017)... , March 29, 2017 Varian Medical Systems ... report results for the second quarter of fiscal year 2017 ... 2017.  The news release will be followed by a teleconference ... news release and a link to the conference call webcast ... .  To access the teleconference call and replay: ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The Professional Squash Association, ... enlisted New York City-based sports and entertainment marketing firm Leverage Agency as its ... for the Professional Squash Association (PSA), which includes first-time ever title sponsorship, naming ...
(Date:3/29/2017)... ... ... pollen is the main cause of hay fever in the United States, with an estimated ... from May to July each year; with the worst time for sufferers being June and ... ( http://www.haymax.us ) provide an effective defense against grass pollen; they are proven in independent ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Youth Futures ... great success and feedback from high school and college students who have participated in ... held July 7-23 and YFI is now accepting applications for enrollment. Visit ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sports Brand ... brace, which retails normally at $29.97; for the remaining days of March, the ... also been reduced to a special price of just $10 (regular retail price $19.97). ...
(Date:3/29/2017)... Louisiana (PRWEB) , ... March 29, 2017 , ... ... in three Hours at a Walgreens store in Mississippi. AngioGenesis Labs, makers of ... Walgreens Stores in two southeastern states. Ingredients in HeartBoost, an over the counter ...
Breaking Medicine News(10 mins):